Efficacy of the fixed-dose combination of amlodipine/perindopril/atorvastatin in patients with hypertension and dyslipidemia in real-world practice. Results of the TARGET study.

Objectives. The primary objective was to describe antihypertensive and lipid lowering effectiveness of a polypill of amlodipine, atorvastatin, and perindopril at week 12 in patients with arterial hypertension (HTN) and hypercholesterolemia in daily clinical practice. Design and method. The TARGET study (NCT05764317) was a 12-week ambispective observational study. Adult out-patients with HTN and hypercholesterolemia had initiated treatment with the polypill in dosage strengths of 5/10/5 mg; 5/20/5 mg or 5/20/10 mg within 1 month before enrollment. The primary outcome was mean change from baseline in office systolic and diastolic blood pressure (SBP, DBP) and low-density lipoprotein cholesterol (LDL-C) at week 12. Main secondary outcomes were changes of quality of life as assessed by SF-36 questionnaire and adherence to therapy measured by a Russian questionnaire at week 12 compared to baseline. Effectiveness and safety analyses were performed in modified intention-to-treat population. Uni and multivariate regression models were used to define significant predictors for the achievement of target parameters. Results. Four hundred nine outpatients who had already initiated the polypill of amlodipine/atorvastatin/perindopril were included in the study. Very high or extreme cardiovascular (CV) risk initially had 160 (39.1%) of patients, 166 (40.6%) had high CV risk, 71 (17.4%) had moderate and 12 (2.9%) had low CV risk. Mean baseline blood pressure (BP, SD) was 157.3 (15.6)/ 92.3 (9.1) mmHg and mean LDL-C at baseline was 3.7 (1.0) mmol/L. Mean SBP decreased by 32.4 (15.3) mmHg and DBP by 15.0 (10.0) mmHg by week 12 (both р<0.0001). Mean LDL-C value decreased by 1.6 (0.9) mmol/L (р<0.0001). Changes in physical and psychological components of SF-36 were 5.7 (8.2) and 7.7 (9.9) points by week 12 compared to baseline. Proportion of patients with low/moderate adherence decreased from 17.4% (71/409) to 1.5% (6/409) by week 12, whereas a proportion of patients with a high adherence at the end of the observation period increased up to 97.5%. Older age (OR (odds ratio) 0.97, 95% confidence interval (CI) 0.94 to 0.99) and peripheral artery disease (PAD) (OR 0.44, 95% CI 0.22 to 0.91) were significant negative predictors for achieving target BP. Presence of T2D (OR 0.50, 95% CI 0.28 to 0.89) and LDL-C level increase by week 12 compared to baseline (OR 0.28, 95% CI 0.21 to 0.39) were negative predictors for LDL-C target value achievement. One non-serious adverse event (dry cough) and one special situation (insufficient lipid-lowering effectiveness) were reported. Conclusion. Treatment with a polypill amlodipine/atorvastatin/perindopril demonstrated significant BP and lipid-lowering effectiveness and was well tolerated. These changes were accompanied by improvement of adherence to treatment and quality of life.

1. Masenga SK, Kirabo A. Hypertensive heart disease: risk factors, complications and mechanisms. Front Cardiovasc Med. 2023;10:1205475. https://doi.org/10.3389/fcvm.2023.1205475

2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957 80. https://doi.org/10.1016/S0140-6736(21)01330-1

3. Баланова Ю.А., Драпкина О.М., Куценко В.А. и соавт. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространенности, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кар диоваскулярная терапия и профилактика. 2023;22(8S):3785. EDN: YRUNUX. https://doi.org/10.15829/1728-8800-2023-3785 [Balanova Yu.A., Drapkina O.M., Kutsenko V.A., et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) https://doi.org/10.15829/1728-8800-2023-3785 ]

4. Meher M, Pradhan S, Pradhan SR. Risk factors associated with hypertension in young adults: a systematic review. Cureus. 2023;12;15(4):e37467. https://doi.org/10.7759/cureus.37467

5. Laufs U, Catapano AL, De Caterina R et al. The effect of the 2019 ESC/ EAS dyslipidaemia guidelines on low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: the ACS EuroPath IV project. Vascul Pharmacol. 2023;148:107141. https://doi.org/10.1016/j.vph.2023.107141

6. Roth GA, Mensah GA, Johnson CO et al/. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982-3021. https://doi.org/10.1016/j.jacc.2021.02.039

7. Vaduganathan M, Mensah GA, Turco JV et al. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80(25):2361-71. https://doi.org/10.1016/j.jacc.2022.11.005

8. Ference BA, Bhatt DL, Catapano AL et al. Association of genetic variants related to combined exposure to lower low-density lipoproteins and lower systolic blood pressure with lifetime risk of cardiovascular disease. JAMA. 2019;322(14):1381-91. https://doi.org/10.1001/jama.2019.14120

9. Lee EKP, Poon P, Yip BHK et al. Global burden, regional differences, trends, and health consequences of medication nonadherence for hypertension during 2010 to 2020: a meta-analysis involving 27 million patients. J Am Heart Assoc. 2022;11(17):e026582. https://doi.org/10.1161/JAHA.122.026582

10. Ротарь О.П., Ильянова И.Н. Бояринова М.А. и соавт. Результаты Всероссийского скрининга артериальной гипертензии. Российский кардиологический журнал 2024;29(5):5931. EDN: EMCJRB. https://doi.org/10.15829/1560-4071-2024-5931 [Rotar O.P., Ilyanova I.N., Boyarinova M.A., et al. 2023 All-Russian screening for hypertension: results. Russian Journal of Cardiology. 2024;29(5):5931. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5931 ]

11. Алиева А.С., Усова А.С, Звартау Н.Э., Е.В. Шляхто и соавт. Результаты первого этапа имплементационного исследования по внедрению клинических рекомендаций по нарушениям липидного обмена в рутинную практику. Российский кардиологический журнал. 2024;29(1):5724. EDN: ADVLHL. https://doi.org/10.15829/1560-4071-2024-5724 [Alieva A.S., Usova E.I., Zvartau N.E., Shlyakhto E.V. Implementation study to introduce clinical guidelines on lipid metabolism disorders into routine practice: results of the first stage. Russian Journal of Cardiology. 2024;29(1):5724. (In Russ.) https://doi.org/10.15829/1560-4071-2024-5724 ]

12. Шальнова С.А., Белова В.Н., Валиахметов М.Н. и соавт. .Пути увеличения приверженности терапии статинами. Кардиоваскулярная терапия и профилактика. 2018;17(2):81-7. (In Russ.) https://doi.org/10.15829/1728-8800-2018-2-81-87 [Shalnova S.A., Belov V.N., Valiakhmetov M.N., et al. Approaches to statin therapy adherence improvement. Cardiovascular Therapy and Prevention. 2018;17(2):81-87. (In Russ.) https://doi.org/10.15829/1728-8800-2018-2-81-87 ]

13. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407. https://doi.org/10.1161/HYPERTENSIONAHA.109.139816

14. McEvoy JW, McCarthy CP, Bruno RM et al. ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. https://doi.org/10.1093/eurheartj/ehae178

15. Кобалава Ж.Д., Конради А.О., Недогода С.В. и соавт. . Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал 2024;29(9):6117. EDN: GUEWLU. https://doi.org/10.15829/1560-4071-2024-6117 [Kobalava Zh.D., Konradi A.O., Nedogoda S.V., et al. 2024 Clinical practice guidelines for Hypertension in adults. Russian Journal of Cardiology. 2024;29(9):6117. (In Russ.) https://doi.org/10.15829/1560-4071-2024-6117 ]

16. Чазова И.Е., Чихладзе Н.М., Блинова Н.В. и соавт. Клинические рекомендации Российского медицинского общества по артериальной гипертонии (РМОАГ) и Евразийской Ассоциации Карди ологов (ЕАК) по диагностике и лечению артериальной гипертонии (2024). Системные гипертензии 2024;21(4):5-110. https:// doi.org/10.38109/2075-082x-2024-4-5-109 [Chazova I.E., Chikhladze N.M., Blinova N.V., et al. Clinical guidelines of the Russian Medical Society on arterial Hypertension (RSH) and the Eurasian association of Cardiologists (EaC) for the diagnosis and treatment of arterial hypertension (2024). Systemic Hypertension. 2024;21(4):5-110. (In Russ.) https://doi.org/10.38109/2075-082X-2024-4-5-109 ]

17. Sedhom R, Hamed M, Tan W et al. Meta-Analysis on the Clinical Outcomes With Polypills for Cardiovascular Disease Prevention. Am J Cardiol. 2023 Aug 15;201:211-218. https://doi.org/10.1016/j.amjcard.2023.06.001

18. Simon A, Dézsi CA. Treatment of Hypertensive and Hypercholesterolaemic patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study. Adv Ther. 2019 Aug;36(8):2010-2020. https://doi.org/10.1007/s12325-019-01002-8

19. Кобалава Ж.Д., Конради А.О., Недогода С.В., и соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал 2020;25(3):3786. https://doi.org/10.15829/1560-4071-2020-3-3786 [Kobalava Zh.D., Konradi A.O., Nedogoda S.V., et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.) https://doi.org/10.15829/1560-4071-2020-3-3786 ]

20. Williams B, Mancia G, Spiering W et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018 Sep 1;39(33):3021-3104. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475. https://doi.org/10.1093/eurheartj/ehy339

21. Кухарчук В.В., Ежов М.В., Сергиенко И.В. и соавт. Клинические рекомендации евразийской ассоциации кардиологов (ЕАК) На ционального общества по изучению атеросклероза (НОА, Рос сия) по диагностике и коррекции нарушений липидного обмена с целью профилактики и лечения атеросклероза (2020) Евразийский Кардиологический Журнал. 2020; (2):6-29 https://doi.org/10.38109/2225-1685-2020-2-6-29 [Kukharchuk V.V., Ezhov M.V., Sergienko I.V., et al. Eurasian Association Of Cardiology (EAC)/ Russian National Atherosclerosis Society (RNAS, Russia) guidelines for the diagnosis and correction of dyslipidemia for the prevention and treatment of atherosclerosis (2020). Eurasian heart journal. 2020;(2):6-29. (In Russ.) https://doi.org/10.38109/2225-1685-2020-2-6-29 ]

22. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455

23. Lasserson DS, Buclin T, Glasziou P. How quickly should we titrate antihypertensive medication? Systematic review modelling blood pressure response from trial data. Heart. 2011;97:1771e1775. https://doi.org/10.1136/hrt.2010.221473

24. Cushman WC, Ford CE, Cutler JA et al. Success and predictors of blood pressure control in diverse North American settings: antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens. 2002;4(6):393-404. https://doi.org/10.1111/j.1524-6175.2002.02045.x

25. Sever PS, Dahlöf B, Poulter NR et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-58. https://doi.org/10.1016/S0140-6736(03)12948-0

26. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423. https://doi.org/10.1136/bmj.326.7404.1423

27. Li J, Zhang Z, Si S, Wang B, Xue F. Antihypertensive medication adherence and cardiovascular disease risk: a longitudinal cohort study. Atherosclerosis. 2021;320:24-30. https://doi.org/10.1016/j.atherosclerosis.2021.01.005

28. Khunti K, Danese MD, Kutikova L et al. Association of a combined measure of adherence and treatment intensity with cardiovascular outcomes in patients with atherosclerosis or other cardiovascular risk factors treated with statins and/or ezetimibe. JAMA Network Open. 2018;1(8):e185554. https://doi.org/10.1001/jamanetworkopen.2018.5554

29. Del Pinto R, Desideri G, Ferri C et al. Real-world antihypertensive treatment patterns, treatment adherence, and blood pressure control in the elderly: an Italian awareness-raising campaign on hypertension by Senior Italia FederAnziani, the Italian Society of Hypertension and the Italian Federation of General Practitioners. High Blood Press Cardiovasc Prev. 2021;28(5):457-66. https://doi.org/10.1007/s40292-021-00465-7

30. Borghi C, Jayagopal PB, Konradi A et al. Adherence to triple single pill combination of perindopril/indapamide/amlodipine: findings from real-world analysis in Italy. Adv Ther. 2023; 40(4):1765-72. https://doi.org/10.1007/s12325-023-02451-y

31. Serban MC, Colantonio LD, Manthripragada AD et al. Statin intolerance and risk of coronary heart events and all-cause mortality following myocardial infarction. J Am Coll Cardiol. 2017;69:1386 95. https://doi.org/10.1016/j.jacc.2016.12.036

32. Navar AM, Roe MT, White JA et al. Medication Discontinuation in the IMPROVE-IT Trial. Medication discontinuation in the IMPROVE IT trial. Circ Cardiovasc Qual Outcomes. 2019;12(1):e005041. https://doi.org/10.1161/CIRCOUTCOMES.118.005041

33. Boklage SH, Malangone-Monaco E, Lopez-Gonzalez L et al. Statin utilization patterns and outcomes for patients with acute coronary syndrome during and following inpatient admissions. Cardiovasc Drugs Ther. 2018;32(3):273-80. https://doi.org/10.1007/s10557-018-6800-3

34. Weisser B, Predel HG, Gillessen A et al. Single pill regimen leads to better adherence and clinical outcome in daily practice in patients suffering from hypertension and/or dyslipidemia: results of a meta analysis. High Blood Press Cardiovasc Prev. 2020;27(2):157-64. https://doi.org/10.1007/s40292-020-00370-5

35. Lee CJ, Park WJ, Suh JW et al. Relationship between health-related quality of life and blood pressure control in patients with uncontrolled hypertension. J Clin Hypertens (Greenwich). 2020;22(8):1415-24. https://doi.org/10.1111/jch.13941

36. Norman G.R., Sloan J.A., Wyrwich K.W. Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation. Med Care 2003; 41:582-592. https://doi.org/10.1097/01.mlr.0000062554.74615.4c

37. Masterson Creber R, Dimagli A, Niño de Rivera S et al. Minimal clinically important differences in patient-reported outcomes after coronary artery bypass surgery in the arterial revascularization trial. Eur J Cardiothorac Surg. 2024 Jul 1;66(1):ezae208. https://doi.org/10.1093/ejcts/ezae208

38. Thom S, Poulter N, Field J. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA. 2013;310(9):918-929. https://doi.org/10.1001/jama.2013.277064

39. Chapman RH, Petrilla AA, Benner JS et al. Predictors of adherence to concomitant antihypertensive and lipid-lowering medications in older adults: a retrospective, cohort study. Drugs Aging. 2008;25(10):885-92. https://doi.org/10.2165/00002512-200825100-00008

40. Kobalava Z, Kvasnikov B, Burtsev Y. PRIDE study investigators. Effectiveness and Tolerability of Bisoprolol/Perindopril Single-Pill Combination in Patients with Arterial Hypertension and a History of Myocardial Infarction: The PRIDE Observational Study. Adv Ther. 2023;40(6):2725-40. https://doi.org/10.1007/s12325-023-02462-9

41. Mazzaglia G, Ambrosioni E, Alacqua M et al. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120(16):1598-605. https://doi.org/10.1161/CIRCULATIONAHA.108.830299

42. Costa Filho FF, Timerman A, Saraiva JFK et al. Independent predictors of effective blood pressure control in patients with hypertension on drug treatment in Brazil. J Clin Hypertens (Greenwich). 2018;20(1):125-32. https://doi.org/10.1111/jch.13139

43. Zemaitis MR, Boll JM, Kato M, Golla MSG. Peripheral Arterial Disease. 2025 Dec 1. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 28613496. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430745/

44. Nordanstig J, Behrendt CA, Bradbury AW et al. Peripheral arterial disease (PAD) – A challenging manifestation of atherosclerosis. Prev Med. 2023;171:107489. https://doi.org/10.1016/j.ypmed.2023.107489

45. Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database Syst Rev. 2013 Dec 4;2013(12):CD003075. https://doi.org/10.1002/14651858.CD003075.pub3

46. Семенцова Н.А., Чесникова А.И., Сафроненко В.А., Скаржинская Н.С. Особенности артериальной ригидности у пациентов с артериальной гипертензией и атеросклерозом артерий нижних конечностей. Артериальная гипертензия. 2022;28(4):386-95. https://doi.org/10.18705/1607-419X-2022-28-4-386-395 [Sementsova N.A., Chesnikova A.I., Safronenko V.A., Skarzhinskaya N.S. Arterial stiffness in hypertensive patients with peripheral artery disease. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2022;28(4):386-395. (In Russ.) https://doi.org/10.18705/1607-419X-2022-28-4-386-395]

47. Mancia G, Kreutz R, Brunström M et al. Guidelines for the management of arterial hypertension. J Hypertens. 2023;41(12):1874-2071. https://doi.org/10.1097/HJH.0000000000003480

48. Клинические рекомендации по лечению сахарного диабета 2 типа. Министерство здравоохранения РФ от 2022 года. [Clinical guidelines for the treatment of type 2 diabetes mellitus. Ministry of Health of the Russian Federation, 2022. (In Russ.)]